We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Marker Therapeutics Inc (MRKR) USD0.001

Sell:$3.88 Buy:$4.87 Change: $0.0099 (0.25%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Sell:$3.88
Buy:$4.87
Change: $0.0099 (0.25%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Sell:$3.88
Buy:$4.87
Change: $0.0099 (0.25%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It has three multiTAA-specific T cell therapies through clinical development, including Autologous multiTAA-specific T cell therapies, Allogeneic multiTAA-specific T cell therapies and Off-the-shelf multiTAA-specific T cell therapies. It is also focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer. Autologous multiTAA-specific T cell therapies target the NY-ESO-1, PRAME, MAGE-A4, Survivin and SSX2 antigens.

Contact details

Address:
4551 KENNEDY COMMERCE DR.
HOUSTON
77032
United States
Telephone:
+1 (713) 4006400
Website:
https://markertherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MRKR
ISIN:
US57055L2060
Market cap:
$34.84 million
Shares in issue:
8.89 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Juan Vera
    President, Chief Executive Officer, Principal Financial and Accounting Officer, Director
  • Gerald Garrett
    Vice President - Clinical Operations
  • Nadia Agopyan
    Vice President - Regulatory Affairs
  • Anna Szymanska
    Vice President - Quality
  • Tsvetelina Hoang
    Vice President - Research and Development
  • Monic Stuart
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.